The Use of Mandated Public Disclosures of Clinical Trials as Prior Art Against Study Sponsors
Patently-O
APRIL 16, 2024
Pharmaceutical innovators are voicing concern that these disclosures are increasingly being used as prior art to invalidate patents arising out of, or otherwise relating to, these trials, in a manner that threatens to disincentivize investment in pharmaceutical innovation. A recent Federal Circuit decision, Salix Pharms., Teva Pharms.
Let's personalize your content